Future Long Range Assault Aircraft Medical Evacuation and Special Operations Procurement Act of 2025
SB 2075, the Future Long Range Assault Aircraft Medical Evacuation and Special Operations Procurement Act of 2025, would authorize the Secretary of the Army to accelerate research, development, testing, evaluation, and initial procurement of two specific variants of the Future Long Range Assault Aircraft (FLRAA). One variant is a medical evacuation configuration intended to improve patient care, survivability, telemedicine integration, patient capacity, and operational reach. The other is a special operations configuration tailored for U.S. Special Operations Command, with advanced sensors, weapons systems, launched effects, and modular mission packages.
The bill directs the Army to coordinate development with the Army Medical Department and USSOCOM, pursue rapid prototyping and user evaluation, and maximize commonality across FLRAA variants to reduce long-term acquisition and sustainment costs. It also requires a report to Congress within 180 days on development status, testing, timelines for milestones and fielding, and anticipated future funding needs. The bill does not itself provide new appropriations; any development or procurement would depend on funds already provided in appropriations acts.
If enacted, the bill would amend federal defense acquisition policy by expressly allowing the Army to speed up work on FLRAA MEDEVAC and special operations variants before full-rate production. It would not create a new funding stream or mandate spending, but it would shape Army procurement priorities, require interagency coordination within the Department of Defense, and impose a congressional reporting obligation on the Secretary of the Army. The practical effect would be to accelerate planning and early acquisition for military aviation capabilities tied to battlefield medical evacuation and special operations missions.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears supportive and operationally focused. The measure is framed as a readiness and modernization initiative, emphasizing faster development, improved survivability, and cost control through common systems. There is no evidence in the provided record of organized opposition, amendments, or partisan controversy at this stage, and the bill was simply read twice and referred to the Senate Armed Services Committee.
The main potential points of contention are likely to be the pace of procurement, the scope of mission-specific capabilities, and whether accelerating these variants could increase technical or budgetary risk. Supporters would likely favor the bill’s emphasis on rapid prototyping, medical evacuation improvements, and special operations utility, while skeptics may question whether early acceleration could outpace testing or create sustainment costs despite the commonality requirement. Another possible issue is that the bill authorizes acceleration without providing new appropriations, leaving implementation dependent on future or existing defense funding.